Icon (ICLR) – Analysts’ Recent Ratings Changes
by Scott Moore · The Cerbat GemSeveral analysts have recently updated their ratings and price targets for Icon (NASDAQ: ICLR):
- 12/15/2025 – Icon had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
- 12/15/2025 – Icon had its price target raised by analysts at Barclays PLC from $185.00 to $200.00. They now have an “equal weight” rating on the stock.
- 12/15/2025 – Icon was downgraded by analysts at Bank of America Corporation from a “buy” rating to a “neutral” rating. They now have a $195.00 price target on the stock.
- 12/1/2025 – Icon had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
- 11/25/2025 – Icon had its “hold (c-)” rating reaffirmed by analysts at Weiss Ratings.
- 11/25/2025 – Icon was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating.
- 11/13/2025 – Icon is now covered by analysts at BMO Capital Markets. They set a “market perform” rating and a $175.00 price target on the stock.
- 10/27/2025 – Icon was downgraded by analysts at Zacks Research from a “hold” rating to a “strong sell” rating.
- 10/24/2025 – Icon had its “hold” rating reaffirmed by analysts at Cowen Inc.
- 10/24/2025 – Icon was given a new $220.00 price target on by analysts at UBS Group AG.
- 10/24/2025 – Icon was given a new $220.00 price target on by analysts at Robert W. Baird.
- 10/24/2025 – Icon had its price target lowered by analysts at TD Cowen from $183.00 to $172.00. They now have a “hold” rating on the stock.
- 10/24/2025 – Icon had its price target lowered by analysts at Barclays PLC from $190.00 to $185.00. They now have an “equal weight” rating on the stock.
- 10/23/2025 – Icon was given a new $220.00 price target on by analysts at Leerink Partners.
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Stories
- Five stocks we like better than Icon
- How to trade using analyst ratings
- Post 35% Surge, Analysts Eye More Upside in Copper Giant Freeport
- Health Care Stocks Explained: Why You Might Want to Invest
- Why a SpaceX IPO Could Be a Major Catalyst for GOOGL Stock
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Can Upwork Maintain Its Comeback? Reasons to Be Bullish and Bearish